(4-Propan-2-ylphenyl) methanesulfonate | 1062267-15-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-Propan-2-ylphenyl) methanesulfonate
• 英文别名: (4-propan-2-ylphenyl) methanesulfonate
• CAS: 1062267-15-5
• 化学式: C₁₀H₁₄O₃S
• 分子量: 214.285
• InChiKey: FVVXWYZQQRZQGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-Propan-2-ylphenyl) methanesulfonate 在 6-chloro-4-trifluoromethyl-1,2,3-benzoxathiazine-2,2-dioxide 、 Oxone 作用下， 以 水 为溶剂， 反应 12.0h， 以55%的产率得到[4-(2-Hydroxypropan-2-yl)phenyl] methanesulfonate
  参考文献：
  名称：

  Organocatalytic C–H hydroxylation with Oxone^®enabled by an aqueous fluoroalcohol solvent system

  摘要：

  使用非金属基催化剂体系、Oxone 作为末端氧化剂和水性氟代醇溶剂混合物，可以实现 3° 和苄基 C–H 键的选择性羟基化。溶剂的选择对于该过程是独特有效的，但似乎与我们发现水促进氧氮丙啶中间体还原的发现不一致。我们的研究表明，羟基化反应发生在氟代醇微滴内，既浓缩了反应物，又减轻了水对氧氮丙啶稳定性的有害影响。这些发现显着改善了碳氢化合物底物的有机催化氧化，并首次成功地将 Oxone 与该催化剂体系结合使用。反应通常会产生接近定量的产物和未反应的起始原料，并且对 3° 和苄基 C–H 键氧化表现出出色的选择性。

  DOI：

  10.1039/c3sc52649f

文献信息

• [EN] SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE SHP2 PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：RELAY THERAPEUTICS INC

  公开号：WO2019165073A1

  公开（公告）日：2019-08-29

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

  本公开涉及新颖化合物及其药物组合物，以及利用本公开的化合物和组合物抑制SHP2磷酸酶活性的方法。本公开还涉及但不限于利用本公开的化合物和组合物治疗与SHP2失调相关的疾病的方法。
• N-Heterocyclic Carbene–Palladium(II)–1-Methylimidazole Complex-Catalyzed Suzuki–Miyaura Coupling of Aryl Sulfonates with Arylboronic Acids
  作者：Zhan-Yong Wang、Gao-Qi Chen、Li-Xiong Shao

  DOI：10.1021/jo301270t

  日期：2012.8.3

  the Suzuki–Miyaura coupling of aryl sulfonates including tosylates and phenylsulfonates with arylboronic acids, giving the desired coupling products in good to high yields. Acceptable yields can also be achieved even by using the less reactive mesylates as the substrates. It is worthy of noting here that this is the first example of NHC–Pd(II) complex-catalyzed Suzuki–Miyaura coupling of aryl sulfonates

  人们发现，定义明确的NHC-Pd（II）-Im配合物1是Suzuki-Miyaura将芳基磺酸盐（包括甲苯磺酸盐和苯磺酸盐）与芳基硼酸偶联的有效催化剂，从而以高至高收率提供了所需的偶联产物。即使通过使用反应性较低的甲磺酸酯作为底物也可以达到可接受的产率。在此值得注意的是，这是NHC-Pd（II）络合物催化的芳基磺酸盐与芳基硼酸的Suzuki-Miyaura偶联的第一个实例，为合成联芳基化合物提供了一种廉价，方便且可替代的方法。
• Organocatalytic C–H hydroxylation with Oxone^®enabled by an aqueous fluoroalcohol solvent system
  作者：Ashley M. Adams、J. Du Bois

  DOI：10.1039/c3sc52649f

  日期：——

  Selective hydroxylation of 3° and benzylic C–H bonds is made possible using a non-metal-based catalyst system, Oxone as the terminal oxidant, and an aqueous fluoroalcohol solvent mixture. The choice of solvent is uniquely effective for this process, but seemingly at odds with our finding that H2O promotes reduction of the oxaziridine intermediate. Our studies suggest that the hydroxylation reaction is occurring within a fluoroalcohol microdroplet, which both concentrates the reactants and mitigates the deleterious impact of H2O on oxaziridine stability. These discoveries have led to demonstrable improvements in the organocatalytic oxygenation of hydrocarbon substrates and, for the first time, the successful use of Oxone with this catalyst system. Reactions generally afford product and unreacted starting material in near quantitative amounts and display outstanding selectivity for 3° and benzylic C–H bond oxidation.

  使用非金属基催化剂体系、Oxone 作为末端氧化剂和水性氟代醇溶剂混合物，可以实现 3° 和苄基 C–H 键的选择性羟基化。溶剂的选择对于该过程是独特有效的，但似乎与我们发现水促进氧氮丙啶中间体还原的发现不一致。我们的研究表明，羟基化反应发生在氟代醇微滴内，既浓缩了反应物，又减轻了水对氧氮丙啶稳定性的有害影响。这些发现显着改善了碳氢化合物底物的有机催化氧化，并首次成功地将 Oxone 与该催化剂体系结合使用。反应通常会产生接近定量的产物和未反应的起始原料，并且对 3° 和苄基 C–H 键氧化表现出出色的选择性。
• ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY
  申请人：Ghosh Arun K.

  公开号：US20100286145A1

  公开（公告）日：2010-11-11

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

  本发明提供了新型的β-分泌酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。
• SHP2 phosphatase inhibitors and methods of use thereof
  申请人：Relay Therapeutics, Inc.

  公开号：US11529347B2

  公开（公告）日：2022-12-20

  The present invention relates to novel compounds having the general formula: and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.

  本发明涉及具有通式的新型化合物： 及其药物组合物，以及用本发明化合物和组合物抑制SHP2磷酸酶活性的方法。本发明进一步涉及但不限于抑制肿瘤细胞生长、改善系统性红斑狼疮的发病机理以及治疗其他各种疾病的方法，包括努南综合征、糖尿病、中性粒细胞减少症、神经母细胞瘤、黑素瘤、幼年白血病、肌瘤、白血病、白血病综合征、白血病、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、黑素瘤、幼年白血病、幼年髓单核细胞白血病、慢性髓单核细胞白血病、急性髓性白血病以及其他与 SHP2 失调相关的癌症，可单独使用或与其他疗法联合使用本发明的化合物和组合物。与SHP2失调相关的其他癌症包括HER2阳性乳腺癌、三阴性乳腺癌、乳腺导管癌、浸润性乳腺导管癌、非小细胞肺癌、食管癌、胃癌、头颈部鳞状细胞癌（SCCHN）和结肠癌。